Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease.

[1]  Merlin C. Thomas,et al.  Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. , 2004, Journal of the American Society of Nephrology : JASN.

[2]  Merlin C. Thomas,et al.  Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. , 2004, Diabetes.

[3]  S. Vatner,et al.  Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. , 2003, American journal of physiology. Heart and circulatory physiology.

[4]  G. Jerums,et al.  The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Merlin C. Thomas,et al.  A Breaker of Advanced Glycation End Products Attenuates Diabetes‐Induced Myocardial Structural Changes , 2003, Circulation research.

[6]  A. Enomoto,et al.  An inhibitor of advanced glycation end product formation reducesNϵ-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats , 2003 .

[7]  A. Enomoto,et al.  An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  T. Kislinger,et al.  RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice , 2002, Circulation.

[9]  M. Cooper,et al.  Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice , 2002, Circulation.

[10]  S. S. Samra,et al.  Accelerated atherosclerosis. , 2002, Journal of the Indian Medical Association.

[11]  V. D’Agati,et al.  Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[12]  G. Romeo,et al.  The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. , 2000, Diabetes.

[13]  D. Choudhury,et al.  Advanced glycation end products: a Nephrologist's perspective. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  R. Nagaraj,et al.  Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. , 1999, Archives of biochemistry and biophysics.

[15]  Alan W. Stitt,et al.  Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. , 1998, Investigative ophthalmology & visual science.

[16]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[17]  M. Nangaku,et al.  Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. , 1998, Biochemical and biophysical research communications.

[18]  G. Jerums,et al.  Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. , 1996, Kidney international.

[19]  A. Schmidt,et al.  Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[20]  G. Jerums,et al.  Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.

[21]  A. Cerami,et al.  Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. , 1988, Diabetes/metabolism reviews.

[22]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[23]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.